Technical Analysis for VTGN - VistaGen Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.7439 -2.12% -0.02
VTGN closed down 2.12 percent on Monday, May 20, 2019, on 31 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical VTGN trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -2.12%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.12%
Wide Bands Range Expansion -2.12%
Up 3 Days in a Row Strength -2.12%
Up 4 Days in a Row Strength -2.12%
1,2,3 Retracement Bearish Bearish Swing Setup -0.15%

Older signals for VTGN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Health Biopharmaceutical Pharmaceutical Industry Diseases Drug Discovery Clinical Trial Disorders Health Sciences Regenerative Medicine Pharmaceutical Sciences Major Depressive Disorder Antidepressants Treatment Of Major Depressive Disorder Clinical Pharmacology Chemical Entities Drug Metabolism Nmda Receptor Antagonists
Is VTGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.44
52 Week Low 0.52
Average Volume 398,543
200-Day Moving Average 1.46
50-Day Moving Average 1.0481
20-Day Moving Average 0.7743
10-Day Moving Average 0.6296
Average True Range 0.0781
ADX 32.61
+DI 21.9595
-DI 27.486
Chandelier Exit (Long, 3 ATRs ) 0.9557
Chandelier Exit (Short, 3 ATRs ) 0.7543
Upper Bollinger Band 1.2375
Lower Bollinger Band 0.3111
Percent B (%b) 0.47
BandWidth 119.643549
MACD Line -0.117
MACD Signal Line -0.1425
MACD Histogram 0.0255
Fundamentals Value
Market Cap 6.97 Million
Num Shares 9.38 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -0.55
Price-to-Sales 7.65
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.80
Resistance 3 (R3) 0.80 0.78 0.79
Resistance 2 (R2) 0.78 0.77 0.78 0.79
Resistance 1 (R1) 0.76 0.76 0.75 0.76 0.79
Pivot Point 0.74 0.74 0.74 0.74 0.74
Support 1 (S1) 0.72 0.73 0.71 0.72 0.70
Support 2 (S2) 0.70 0.72 0.70 0.70
Support 3 (S3) 0.68 0.70 0.69
Support 4 (S4) 0.68